Baird Initiates Coverage On Neurogene with Outperform Rating, Announces Price Target of $54
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Joel Beatty has initiated coverage on Neurogene (NASDAQ:NGNE) with an Outperform rating and a price target of $54.
June 11, 2024 | 9:18 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Baird analyst Joel Beatty has initiated coverage on Neurogene with an Outperform rating and a price target of $54.
The initiation of coverage with an Outperform rating and a price target of $54 by a reputable analyst is likely to positively impact Neurogene's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100